LISTED pharmaceutical research firm Pharmaxis has welcomed a positive recommendation from the Pharmaceutical Benefits Advisory Committee for expanded reimbursement for its cystic fibrosis treatment Bronchitol, which has been recommended for PBS listing in combination with reimbursed CF medication Pulmozyme.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Aug 17